#United States #San Francisco #class action suit #GeneDx Holdings #GeneDx lawsuit

Alert for GeneDx Holdings Investors

On July 27, 2026, Hagens Berman Sobol Shapiro LLP announced a class action lawsuit involving GeneDx Holdings Corp. (NASDAQ: WGS). Investors who have experienced substantial losses related to the stock are encouraged to reach out to the firm before the upcoming lead plaintiff deadline, which is set for August 3, 2026. This lawsuit revolves around allegations of securities fraud, making it crucial for affected parties to take action promptly.

Background on GeneDx Holdings

GeneDx Holdings Corp. is known for its advancements in genomic testing, providing essential insights for personalized medicine. However, the recent class action lawsuit has raised questions about the company's integrity and the transparency of its operations. Investors are particularly concerned about claims made by the company's management regarding its acquisition of Fabric Genomics, which was presented as a pivotal strategy for growth and technological synergies.

Core Allegations

The lawsuit contends that GeneDx misled investors with false statements about Fabric Genomics. Allegations include:

• - Misleading Growth Claims: Management purportedly portrayed Fabric as a beneficial technology aimed at generating robust revenue streams and optimizing internal processes, while being aware of significant integration challenges.
• - Integration Issues: It is suggested that executives knew— or at least should have known— about the operational disconnects and other problems that could damage GeneDx’s overall business model. The lawsuit holds that these discrepancies directly impacted the company's financial performance, resulting in misinforming investors.

Significant Disclosures and Market Reaction

The turning point in the case came on May 4, 2026, when GeneDx released underwhelming first-quarter results following the market’s close. Key disclosures from this release included:

• - A missed revenue target for both genomic testing services, which sharply contrasted earlier optimistic projections.
• - A notable reduction in the company's full-year revenue guidance, slashing expected revenue from between $540 million and $550 million down to $475 million to $490 million.
• - An alarming $31.2 million impairment charge linked directly to Fabric Genomics, effectively erasing nearly 94% of the cash spent on the acquisition just a year prior.

The immediate reaction from the market was striking, leading to a 49.2% plunge in the company's share price, resulting in a collapse from $67.93 to $34.51 in mere hours, thus depleting billions in shareholder value.

Next Steps for Affected Investors

Investors who purchased GeneDx stock between April 16, 2025, and May 4, 2026, and have incurred significant losses are urged to act swiftly. You have until August 3, 2026, to apply for the lead plaintiff role in the class action. The court will evaluate applications to identify representatives who reflect the interests of the entire class of affected investors.

If you or someone you know has insights into GeneDx or has incurred losses, visit their website or contact them via 844-916-0895. Additional information regarding the GeneDx case and frequently asked questions can be found online.

Whistleblower Information

For individuals possessing non-public insights regarding GeneDx, there’s an opportunity to assist in the ongoing investigation. Whistleblowers may be eligible for rewards up to 30% of any successful SEC enforcement actions that may arise from their information.

About Hagens Berman

Hagens Berman is a prominent firm specializing in plaintiffs' rights litigation, reinforcing corporate accountability through various high-profile cases. With over $2.9 billion recovered for clients in diverse fields, they remain dedicated to representing investors and protecting their interests.

Stay informed by following Hagens Berman for updates related to the lawsuit and other newsworthy events concerning corporate governance.